Actively Recruiting
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
Led by Mackay Memorial Hospital · Updated on 2025-05-09
300
Participants Needed
1
Research Sites
237 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder
CONDITIONS
Official Title
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women diagnosed with detrusor overactivity defined by involuntary bladder muscle contractions during filling
- Patients who did not respond to anti-muscarinic monotherapy
- Female patients aged between 40 and 90 years
You will not qualify if you...
- Presence of postvoid urine retention before treatment
- Medical conditions or contraindications for solifenacin and mirabegron such as narrow-angle glaucoma and hypertension
- History of cerebrovascular disease, thromboembolic disorders, gallbladder disease
- Known or suspected breast cancer or estrogen-dependent tumors
- Undiagnosed abnormal vaginal bleeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mackay Memorial Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
H
Hui-Hsuan Lau, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here